How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,009 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Role of Stem Cells in Pathophysiology and Therapy of Spondyloarthropathies—New Therapeutic Possibilities? (PubMed)

Role of Stem Cells in Pathophysiology and Therapy of Spondyloarthropathies—New Therapeutic Possibilities? Considerable progress has been made recently in understanding the complex pathogenesis and treatment of spondyloarthropathies (SpA). Currently, along with traditional disease modifying anti-rheumatic drugs (DMARDs), TNF-α, IL-12/23 and IL-17 are available for treatment of such diseases as ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Although they adequately control

Full Text available with Trip Pro

2017 International journal of molecular sciences

182. Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (MK-8259-038)

with spondyloarthropathy and 1 or more of the following spondyloarthritis (SpA) characteristics: • Inflammatory back pain • Arthritis (physician-diagnosed) • Enthesitis (heel) physician-diagnosed (spontaneous pain or tenderness at examination of the site of the insertion of the Achilles tendon or plantar fascia) • Dactylitis (physician-diagnosed) • Psoriasis (physician-diagnosed) • History of physician-diagnosed inflammatory bowel disease (IBD) • History of uveitis confirmed by an ophthalmologist • Good response

2017 Clinical Trials

183. Safety, Tolerability & Pharmacokinetics of LEVI-04 in Healthy Volunteers and Patients With Osteoarthritis Knee Pain

as a blood donor Objection by General Practitioner to trial entry Poor venous access Also for osteoarthritis patients: History of inflammatory arthritis, including rheumatoid arthritis, seronegative spondyloarthropathy (eg ankylosing spondylitis, psoriatic arthritis, inflammatory bowel disease related arthropathy), gout, pseudogout in index knee (as diagnosed by appropriate crystals on aspiration or C-reactive protein elevation during attacks (subjects with gout or pseudogout in a joint other than

2017 Clinical Trials

184. Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration

or other undifferentiated spondyloarthropathy, or Type III Modic changes around the target disc. Clinical suspicion of a full thickness annular tear at the target disc or other abnormal disc morphology. Clinical suspicion of facet pain as primary pain generator. Subjects who test positive for communicable disease, have significant systemic disease, or are prone to infection. Patient who are deemed unsuitable for clinical study participation by the investigator. Contacts and Locations Go to Information

2017 Clinical Trials

185. A Randomised, Double-blind, Phase I/II Study to Evaluate the PK, PD, Safety, and Efficacy Between HLX01 and Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Treatment With DMARDs

, in the opinion of the investigator Pregnant or lactating female subjects, or subjects who are planning to conceive or breastfeed during the study period or within 12 months after the last administration. History of, or current, inflammatory joint disease other than RA (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) or other systemic autoimmune disorder (e.g., systemic lupus erythematosus, inflammatory bowel disease, pulmonary fibrosis, or Felty's syndrome

2017 Clinical Trials

186. The Effects of Intradialytic Exercise in Hemodiafiltration Patients

to 80 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Dialysis vintage more than 3 months Sedentary or light physical activity Exclusion Criteria: recent myocardial infarction (<12 months) recent ischemic stroke (<12months) uncontrolled comorbidities (diabetes/hypertension/heart failure/heart disease/respiratory disease) Life expectancy < 12 months active musculoskeletal problem e.g.) rheumatoid arthritis, spondyloarthropathy

2017 Clinical Trials

187. Description of Spondylarthritis and Validation of ASAS Criteria in West Indian Patients Seen in Consultation of Rheumatology.

of spondyloarthropathies to allow for early diagnosis, Nuclear magnetic resonance imaging (MRI). This approach led to the publication in 2009 of the classification criteria for spondylarthritis, in particular axial spondyloarthritis, as well as a proposal to modify the classification of criteria defined by Mr. Amor (AMOR) and European Spondylarthropathy Study Group (ESSG) criteria, taking into account the potential abnormalities visible in Magnetic Resonance Imaging Nuclear (MRI). The performance (specificity

2017 Clinical Trials

188. Study of Bone Growth in the Sacroiliac Joint After Minimally Invasive Surgery With Titanium Implants

body fracture, piriformis syndrome, femoral acetabular impingement, labral tear or hip osteoarthritis. Patients with low back pain VAS ratings more than 50 should be carefully considered; they should not participate if the investigator believes these non-SIJ conditions would impair improvement from SIJ treatment. SI joint dysfunction due to an alternative explanation such as: Inflammatory sacroiliitis (e.g., ankylosing spondylitis or other HLA-associated spondyloarthropathy) Tumor Infection Acute

2017 Clinical Trials

189. Evaluation of Platelet Rich Plasma (PRP) for Knee Osteoarthritis

medication in any other joint less than 1 month after inclusion; Introduction of any medical or physiotherapeutic intervention in the last 3 months (rehabilitation, acupuncture, cane, orthotics, etc.) for locomotor system; Body Mass Index (BMI) greater than 35. Presence of other types of arthropathies such as rheumatoid arthritis, diffuse connective tissue diseases, microcrystalline arthropathies, spondyloarthropathies and infectious arthropathies. Symptomatic osteoarthritis of hip and feet Presence

2017 Clinical Trials

190. A Study of Infuse® Bone Graft With Mastergraft® Strip and Posterior Fixation for Posterolateral Fusion (PLF) Treatment of Multi-Level Degenerative Lumbosacral Spinal Conditions

or prior history of malignancy. Overt or active bacterial infection, either local or systemic. Has undergone systemic administration of any type of corticosteroid, anti-neoplastic, immunostimulating, or immunosuppressive agents within 30 days prior to implantation of the assigned treatment. Comorbidities precluding subject from being a surgical candidate. History of autoimmune disease known to affect bone metabolism or the spine (e.g., spondyloarthropathies, juvenile arthritis, rheumatoid arthritis

2017 Clinical Trials

191. 99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis

Study Details Study Description Go to Brief Summary: Twenty evaluable patients with clinical suspicion or confirmed diagnosis of spondyloarthritis due to ankylosing spondylitis, or associated with other known clinical conditions like inflammatory bowel disease, psoriatic arthritis, or undifferentiated spondyloarthropathy. Five patients will be recruited in the first part of the trial, as a Proof of Concept (PoC) phase. The PoC phase will assess the imaging potential of 99mTc-rhAnnexin V-128 in terms

2017 Clinical Trials

192. Benepali® PEN Patient Satisfaction Survey

of the training material received. Condition or disease Intervention/treatment Rheumatoid Arthritis Spondyloarthropathies Biological: Benepali Study Design Go to Layout table for study information Study Type : Observational Actual Enrollment : 500 participants Observational Model: Case-Only Time Perspective: Cross-Sectional Official Title: Non-Interventional Observational Study on Patient Satisfaction With the Benepali® Pre-Filled Pen Actual Study Start Date : August 10, 2017 Actual Primary Completion Date

2017 Clinical Trials

193. Safety, Tolerability, PK and PD of Biosimilar Drug Ritumax® Compared to Original Drug MabThera®

be stable within the last 4 weeks prior to screening Exclusion Criteria: The patient will be deemed ineligible for the study meeting any of the following criteria: Other inflammatory arthropathies apart from rheumatoid arthritis (e.g. gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme desease) or other system autoimmune diseases (e.g. systemic lupus erythematosus, inflammatory bowel disease, pneumosclerosis or Felly's syndrome, sclerodermia, inflammatory myopathy

2017 Clinical Trials

194. Chronic Inflammatory Disease, Lifestyle and Treatment Response

(score) Rheumatoid Arthritis: Disease-specific core outcome sets-7 [ Time Frame: week 14-16 ] • C-Reactive protein (mg/l) Rheumatoid Arthritis: Disease-specific core outcome sets-8 [ Time Frame: week 14-16 ] • DAS28-CRP (score) Rheumatoid Arthritis: Disease-specific core outcome sets-9 [ Time Frame: week 14-16 ] • Simplified Disease Activity Index (SDAI) (index) Axial Spondyloarthropathy: Disease-specific core outcome sets-1 [ Time Frame: week 14-16 ] • BASFI (score) Axial Spondyloarthropathy (...) : Disease-specific core outcome sets-2 [ Time Frame: week 14-16 ] • BASDAI (score) Axial Spondyloarthropathy: Disease-specific core outcome sets-3 [ Time Frame: week 14-16 ] • BASMI (score) Axial Spondyloarthropathy: Disease-specific core outcome sets-4 [ Time Frame: week 14-16 ] • Total score for back pain (0-100 mm VAS) Axial Spondyloarthropathy: Disease-specific core outcome sets-5 [ Time Frame: week 14-16 ] • Physician global assessment (0-100 mm VAS) Axial Spondyloarthropathy: Disease-specific core

2017 Clinical Trials

195. A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis

reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment Have had an inadequate response when treated with 1 or more conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) Exclusion Criteria: Current or prior use of biologic agents for treatment of Ps or PsA Evidence of active inflammatory arthritic syndromes or spondyloarthropathies other than PsA Have participated in any study with interleukin 17 (IL-17) antagonists, including

2017 Clinical Trials

196. Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis (PubMed)

Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis Psoriatic arthritis is a part of the family of diseases referred to as spondyloarthropathies, a diverse group of chronic inflammatory disorders with common clinical, radiographic, and genetic features. Peripheral arthritis is the most common symptom of psoriatic arthritis and patients also frequently experience involvement of the entheses, spine, skin, and nails. Due to the diverse clinical spectrum

Full Text available with Trip Pro

2017 Arthritis research & therapy

197. Juvenile Idiopathic Arthritis (PubMed)

subtype, characterized by enthesitis and asymmetric lower-extremity arthritis. This disease subtype represents the childhood form of adult spondyloarthropathies, with human leukocyte antigen-B27 positivity and uveitis but commonly without axial skeleton involvement. Juvenile psoriatic arthritis is characterized by a psoriatic rash, accompanied by arthritis, nail pitting and dactylitis. Disease complications can vary from growth retardation and osteoporosis secondary to treatment and disease activity

Full Text available with Trip Pro

2017 Balkan medical journal

198. Cardiovascular magnetic resonance imaging: clinical implications in the evaluation of connective tissue diseases (PubMed)

. Rheumatoid arthritis and other spondyloarthropathies, systemic lupus erythematosus, inflammatory myopathies, mixed connective tissue diseases (CTDs), systemic sclerosis, vasculitis, and sarcoidosis are among CTDs with serious cardiovascular involvement; this is due to multiple causative factors such as myopericarditis, micro/macrovascular disease, coronary artery disease, myocardial fibrosis, pulmonary hypertension, and finally heart failure. The complicated pathophysiology and the high cardiovascular

Full Text available with Trip Pro

2017 Journal of inflammation research

199. The performance of different classification criteria sets for spondyloarthritis in the worldwide ASAS-COMOSPA study (PubMed)

with SpA by rheumatologists worldwide. Patients were classified according to the European Spondyloarthropathy Study Group (ESSG), modified European Spondyloarthropathy Study Group (mESSG), Amor, modified Amor, Assessment of SpondyloArthritis international Society (ASAS) axial Spondyloarthritis (axSpA), ASAS peripheral spondyloarthritis (pSpA) and ClASsification criteria for Psoriatic Arthritis (CASPAR) criteria. Overlap between the classification criteria sets was assessed for patients with and without

Full Text available with Trip Pro

2017 Arthritis research & therapy

200. Managing morbidity and treatment-related toxicity in patients with ankylosing spondylitis (PubMed)

Managing morbidity and treatment-related toxicity in patients with ankylosing spondylitis AS is the prototypical member of the family of spondyloarthropathies, and is characterized by seronegativity, axial predominance and new bone formation, which underlie symptoms of inflammatory back pain, enthesopathy and extra-articular manifestations, including anterior uveitis, psoriasis and colitis. Patients with AS typically experience a wide variety of morbidities. These include both morbidities

Full Text available with Trip Pro

2017 Rheumatology (Oxford, England)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>